ROS-Scavenger and radioprotective efficacy of the new PrC-210 aminothiol

Radiation Research

Volumn 178, Issue 1, 2012, Pages 57-68

  Peebles, Daniel D ^b   Soref, Cheryl M ^b   Copp, Richard R ^b   Thunberg, Allen L ^b   Fahl, William E ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ProCertus BioPharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMIFOSTINE; AMINOTHIOL; PLASMID DNA; PRC 210; PROPYLENE GLYCOL; PROTEIN P21; RADIOPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; WATER;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL GROWTH; DIPLOIDY; DISEASE SEVERITY; DNA DAMAGE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DERMATITIS; RADIATION MUTAGENESIS; RADIATION PROTECTION; RAT; S PHASE CELL CYCLE CHECKPOINT; SALMONELLA TYPHIMURIUM; SCORING SYSTEM; WESTERN BLOTTING; WHOLE BODY RADIATION;

ANIMALS; CELL CYCLE; CELLS, CULTURED; DIAMINES; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MICE; RADIATION-PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS;

BACTERIA (MICROORGANISMS); MUS; RATTUS; RODENTIA;

EID: 84864484025     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2806.1     Document Type: Article

References (30)

1. Kumar S, Juresic E, Barton M, Shafiq J. Management of skin toxicity during radiation therapy: a review of the evidence. J Med Imag Radiat Oncol 2010; 54:264-79.
2. Krasin MJ, Hoth KA, Hua C, Gray, JM, Wu, S, Xiong, X. Incidence and correlates of radiation dermatitis in children and adolescents receiving radiation therapy for the treatment of paediatric sarcomas. Clin Oncol (R Coll Radiol) 2009; 21:781-5.
3. Hendry JH, Bentzen SM, Dale RG. A modeled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol 1996; 8:297-307.
4. Bese NS, Hendry JH, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007; 68:654-61.
5. Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, et al. EORTC Radiation Oncology and Breast Cancer Groups. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother 2008; 12:565-70.
6. Weiss JF, Landauer MR. History and development of radiationprotective agents. Int J Radiat Biol 2009; 85:539-73.
7. Winczura P, Jassem J. Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev 2010; 36:268-75.
8. Zheng S, Newton GL, Gonick G, Fahey RC, Ward JF. Radioprotection of DNA by thiols: relationship between the net charge on a thiol and its ability to protect DNA. Radiat Res 1988; 114:11-27.
9. Montana GS, Anscher MS, Mansbach CM, Daly N, Delannes M, Carke-Pearson D, et al. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A Phase I/II trial. Cancer 1992; 69:2826-30.
10. Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, et al. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol 2010; 17:94-112.
11. Fahl WE, Copp RR, Ochsner CE, Peebles DD, Fahl KL. Polyamine compounds and compositions for use in conjunction with cancer therapy. US patent US 7,414,154. (http://patft.uspto. gov)
12. Fahl WE, Peebles DD, Copp RR. Amino thiol compounds and compositions for use in conjunction with cancer therapy. US patent US 7,314,959. (http://patft.uspto.gov)
13. Copp RR, Peebles DD, Fahl WE. Synthesis and growth regulatory activity of a prototype member of a new family of aminothiol radioprotectors. Bioorg Medic Chem Letters 2011; 21:7426-30.
14. Stevens CW, Brondyk WH, Burgess JA, Manoharan TH, Haene BG, Fahl WE. Partially transformed, anchorage-independent human diploid fibroblasts result from overexpression of the c-sis oncogene: mitogenic activity of an apparent monomeric plateletderived growth factor 2 species. Mol Cell Biol 1988; 8:2089-96.
15. Kramer DL, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, Porter CW. Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells. Cancer Res 1997; 57:5521-7.
16. Grdina DJ, Constantinou A, Shigematsu N, Murley JS. Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-(aminopropyl) aminoethanethiol (WR-1065). Radiation Res 1994; 38:44-52.
17. Copp RR, Peebles DD, Soref CM, Fahl WE. Radioprotection conferred by PrC-210 aminothiol and its family of analogs. (submitted)
18. Weiss JF. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Envir Hlth Perspect 1997; 105:1473-8.
19. Finney DJ. Statistical aspects of monitoring for dangers in drug therapy. Methods Inf Med 1971; 10:1-8.
20. Patt HM, Tyree EB, Straube RL, Smith DE. Cysteine protection against X irradiation. Science 1949; 110:213-4.
21. Sweeney TR. A survey of compounds from the antiradiation drug development program of the U.S. Army Medical Research Development Command. Washington: Walter Reed Army Institute of Research; 1979.
22. Grdina DJ, Shigematsu N, Dale P, Newton GL, Aguilera JA, Fahey RC. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995; 16:767-74.
23. A service of the US. National Institutes of Health. Clinical Trials.gov. (http://www.clinicaltrials.gov/ct2/results?term¼ethyol)
24. Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol 1996; 23:83-9.
25. Kligerman MM, Turrisi AT 3rd, Urtasun RC, Norfleet AL, Phillips TL, Barkley T, et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14:1119-22.
26. Soref CM, Hacker TA, Fahl WE. A New Orally Active, Aminothiol Radioprotector-Free of Nausea and Hypotension Side Effects at its Highest Radioprotective Doses. Int J Radiat Oncol Biol Phys 2012; 82:701-7.
27. Ellis, H. Marie Curie: discoverer of radium. (http://findarticles. com/p/articles/mi-m0748/is-1-19/ai-n31944651/)
28. Einstein AJ, Moser KW, Thompson RC, et al. Radiation dose to patients from cardiac diagnostic imaging. Circulation 2007; 116:1290-305.
29. Bogdanich W. Radiation offers new cures, and ways to do harm. The New York Times. 2010 Jan 23. Available from: http://www. nytimes.com/2010/01/24/ health/24radiation.html.
30. Langell J, Jennings R, Clark J, et al. Pharmacological agents for the prevention and treatment of toxic radiation exposure in spaceflight. Aviat Space Environ Med 2008; 79:651-60.